List of Articles Parkinson disease

• Open Access Article
  • Abstract Page
  • Full-Text
  
  1 - Neuroprotective Effect of Ghrelin on Substantia Nigra in Parkinson Disease Model Induced -MPTP
  Neda Nikoklam Nazif
  Aim and Background: Parkinson's disease is a progressive central nervous system disorder. This disease is caused by degenerative loss of dopaminergic neurons of midbrain, from substantia nigra to corpus striatum pathway. Ghrelin act as a neuroprotective against Parkinso More

  Aim and Background: Parkinson's disease is a progressive central nervous system disorder. This disease is caused by degenerative loss of dopaminergic neurons of midbrain, from substantia nigra to corpus striatum pathway. Ghrelin act as a neuroprotective against Parkinson disease, and this study aimed to investigate protective effects of ghrelin on the substantia nigra area of brain in Parkinson disease model induced- MPTP. Materials and Methods:Forty male NMRI mice were randomly divided into 5 groups of: control, saline, Parkinson, Parkinson + 0.0002 mg/kg ghrelin, and Parkinson +0.0004 mg/kg ghrelin. The Parkinson disease model was induced by MPTP intraperitoneally injection (25 mg/kg, i.p) for four days. The treatment was started one day after last MPTP inducement, by ghrelin intraperitoneally injection for 30 days. catalepsy was assessed by the means of a standard test bar. The brains were removed from the skull for histology (haematoxylin and eosin stain were used as the main principle), also tumor necrosis factor alpha (TNF-α), and Interleukin 10(IL-10) levels in substantia nigra and corpus striatum was measured using ELISA method. Results:Ghrelin effectively reduces catalepsy levels and reduces the degenerative loss of dopaminergic neurons of substantia nigra pars compacta. It will meaningfully decrease the levels of TNF-α, and positively increases the levels of IL-10 in substantia nigra and corpus striatum. Conclusion: Based on results obtained from this study, we can conclude that ghrelin has a neuroprotective role, improves catalepsy, reduces inflammatory factors, and increase anti-inflammatory factors in Parkinson disease rodent models. Manuscript profile
• Open Access Article
  • Abstract Page
  • Full-Text
  
  2 - The effect of aerobic and resistance exercise with olive extract on VO2 max, PTEN, and AKT in rats with Parkinson's disease
  Seyedeh Soheila Bolhagh Ramin Shabani Donya Sajedi
  Manuscript profile
• Open Access Article
  • Abstract Page
  • Full-Text
  
  3 - The Effect of Magnesium Oxide Nanoparticles on Oxidative Stress in a Parkinson's Model of Male Rats
  Hoda Ghorbani moghaddam Akram Eidi Pejman Mortazavi Shahrbanoo Oryan
  10.22034/ascij.2022.1958259.1392
  Since limited studies have evaluated the antioxidant effects of magnesium oxide nanoparticles on Parkinson's disease, the aim of this study is to investigate the effect of magnesium oxide nanoparticles (MON) on oxidative stress in the Parkinson's model in mice. In this More

  Since limited studies have evaluated the antioxidant effects of magnesium oxide nanoparticles on Parkinson's disease, the aim of this study is to investigate the effect of magnesium oxide nanoparticles (MON) on oxidative stress in the Parkinson's model in mice. In this experimental study, 54 adult male rats were divided into nine groups of six, including: healthy control group, parkinsonian control group receiving 6-hydroxydopamine in the lateral ventricle, sham group receiving normal saline and healthy experimental group receiving magnesium oxide nanoparticles in doses of 2.5, 5 and 10 mg/kg and experimental Parkinson's groups that in addition to inducing Parkinson's, received magnesium oxide nanoparticles in doses of 2.5, 5 and 10 mg/kg. Administration of nanoparticles was intraperitoneal for 30 days. After that, oxidative stress parameters MDA, CAT and SOD were measured in the brain tissue. The results of the present study showed that treatment with magnesium oxide nanoparticles significantly reduced the amount of oxidative stress parameters in the brain tissue (p < 0.05). Magnesium oxide nanoparticle treatment in doses of 5 and 10 mg/kg decreased MDA in parkinsonian groups compared to parkinsonian control animals. Also, the treatment of magnesium oxide nanoparticles in doses of 5 and 10 mg/kg in the parkinsonian group caused a significant increase in the activity of SOD and CAT enzymes compared to parkinsonian control animals. As a result, it can be said that magnesium oxide nanoparticle can play a promising role with its effectiveness in reducing oxidative stress processes in Parkinson's model. Manuscript profile